ACLARAMIENTO ESOFAGICO PDF

¿Qué es el aclaramiento esofágico? ¿Cuáles son los factores agresivos? ¿Cuál es el rol de la Hernia del Hiato? ¿Qué factores de riesgo/protección se asocian. dr marugán tema reflujo gastroesofágico el reflujo es una cuestión de cantidad, todos tenemos reflujo pero cuando ese paso de contenido gástrico es mayor de . mediante pH-metría ambulatoria de 24 horas y un estudio isotópico con radionúclidos para determinar el aclaramiento esofágico de líquidos a largo plazo.

Author: Meziramar Salrajas
Country: Guinea-Bissau
Language: English (Spanish)
Genre: Environment
Published (Last): 7 December 2009
Pages: 489
PDF File Size: 17.14 Mb
ePub File Size: 10.60 Mb
ISBN: 757-9-29500-681-2
Downloads: 46975
Price: Free* [*Free Regsitration Required]
Uploader: Kagam

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.

Pneumonia AND sponsor name. How to search [pdf]. For these items you esofagido use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned.

  ATMEL AT89C51 DATASHEET PDF

EU Clinical Trials Register. Both Female Only Male Only. IMP with orphan designation in the indication.

Cirugía General MIP Flashcards

Trials with results Trials without results. Clear advanced search filters.

Date on which this aclwramiento was first entered in the EudraCT database:. Title of the trial for lay people, in easily understood, i. The IMP has been designated in this indication as an orphan drug in the Community. Committee on Advanced therapies CAT has issued a classification for this product.

MANSONTELOSIS by diana minaya on Prezi

Combination product that includes a device, but does not involve an Advanced Therapy. Esophageal, Gastroesophageal Junction and Gastric Cancer. Testing may be performed by central laboratory prior to main study informed consent if subject signs a separate consent for the purposes of tumor tissue testing – Availability of recent preferred or archival tumor tissue – Esogagico disease per RECIST 1.

Subject is a candidate for curative surgery or definitive chemoradiation. Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment.

Clinical trials

Johns Wort and other herbal supplements known to induce CYP3A4 less than 14 days prior to study day 1. Patient-reported outcomes assessment will be done at baseline and at every radiological assessment thereafter, including radiological assessments to confirm tumour progression when symptoms of disease progression occur.

  ESPRIMO P710 PDF

CTC and circulating serum biomarkers will also be assessed at baseline and during study treatment. Health-related quality of life.

Cirugía General MIP – Online Flashcards by Lilian Puig | Brainscape

The trial involves single site in the Member State concerned. Definition of the end of aclarramiento trial and justification where it is not the last visit of the last subject undergoing the trial.

Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.

Back to top